{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:53:30Z","timestamp":1768568010291,"version":"3.49.0"},"posted":{"date-parts":[[2024,11,15]]},"group-title":"Neurology","reference-count":30,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2024,11,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Ischemic stroke is common among patients with systemic malignancy, associated with increased risk of neurological deterioration and mortality compared to the general population. Optimal approach to secondary stroke prevention in cancer patients is unclear. In this meta-analysis, we evaluated available data on the use of direct oral anticoagulants (DOACs) and heparin products for stroke prevention in this population.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using the Nested Knowledge AutoLit software, we performed PubMed search in September 2023 for articles reporting the use of antithrombotics for cancer-associated stroke. We conducted systematic review and meta-analysis. We also used a novel computational augmentation method to amplify the sample size to predict the effect before and after sample size augmentation and predict the results of further trials.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 253 potential studies screened, 7 were eligible for inclusion. 439 patients were treated with DOACs and 3968 with heparin products. Among patients treated with heparin, intracerebral hemorrhage (8.8 % vs 1.6, p=.02), overall hemorrhagic complications (17.9% vs 3.5%, p&lt;.001), and mortality [28.1% vs 23.5%, p&lt;.001] were respectively significantly higher than those reported among patients who received DOAC for cancer-associated ischemic stroke. No significant difference was observed in the rates of recurrent deep venous thrombosis, clinically significant hemorrhage, and clinical outcomes between the treatment groups. Similar results were shown with augmented meta-analysis.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This meta-analysis shows DOACs may have efficacy and safety profile similar to heparin products for recurrent stroke prevention in patients with cancer. Given the small number of studies and limited data, findings should be interpreted with caution.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2024.11.14.24317340","type":"posted-content","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T19:00:12Z","timestamp":1731697212000},"source":"Crossref","is-referenced-by-count":0,"title":["Direct Oral Anticoagulants vs. Heparin for Cancer-Related Stroke: Augmented Meta-Analysis"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8325-2382","authenticated-orcid":false,"given":"Muhammed Amir","family":"Essibayi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Y.","family":"Azzam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugur","family":"Sener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Altschul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merve","family":"Atik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafer","family":"Keser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2024112003053912000_2024.11.14.24317340v1.1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25227"},{"issue":"11","key":"2024112003053912000_2024.11.14.24317340v1.2","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.mayocp.2022.09.003","article-title":"Ischemic Stroke in Patients With Malignancy","volume":"97","year":"2022","journal-title":"Mayo Clin Proc"},{"key":"2024112003053912000_2024.11.14.24317340v1.3","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.032002"},{"key":"2024112003053912000_2024.11.14.24317340v1.4","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2019.4669"},{"key":"2024112003053912000_2024.11.14.24317340v1.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7954-6"},{"key":"2024112003053912000_2024.11.14.24317340v1.6","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-012-1011-4"},{"key":"2024112003053912000_2024.11.14.24317340v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13120-6"},{"issue":"1","key":"2024112003053912000_2024.11.14.24317340v1.8","first-page":"1039","article-title":"Stroke and Cancer-A Complicated Relationship","volume":"2","year":"2014","journal-title":"J Neurol Transl Neurosci"},{"key":"2024112003053912000_2024.11.14.24317340v1.9","doi-asserted-by":"publisher","DOI":"10.5853\/jos.2019.02278"},{"issue":"11","key":"2024112003053912000_2024.11.14.24317340v1.10","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1161\/STROKEAHA.119.026143","article-title":"Cancer-Related Ischemic Stroke Has a Distinct Blood mRNA Expression Profile","volume":"50","year":"2019","journal-title":"Stroke"},{"key":"2024112003053912000_2024.11.14.24317340v1.11","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198501000-00002"},{"key":"2024112003053912000_2024.11.14.24317340v1.12","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22050"},{"key":"2024112003053912000_2024.11.14.24317340v1.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802686"},{"key":"2024112003053912000_2024.11.14.24317340v1.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813959"},{"key":"2024112003053912000_2024.11.14.24317340v1.15","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000539"},{"key":"2024112003053912000_2024.11.14.24317340v1.16","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.15.1729"},{"issue":"3","key":"2024112003053912000_2024.11.14.24317340v1.17","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jamaneurol.2017.4211","article-title":"Enoxaparin vs Aspirin in Patients With Cancer and Ischemic Stroke: The TEACH Pilot Randomized Clinical Trial","volume":"75","year":"2018","journal-title":"JAMA Neurol"},{"key":"2024112003053912000_2024.11.14.24317340v1.18","doi-asserted-by":"crossref","unstructured":"Sterne JA , Hernan MA , Reeves BC , et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","DOI":"10.1136\/bmj.i4919"},{"key":"2024112003053912000_2024.11.14.24317340v1.19","unstructured":"Altman DG MD , Bryant TN and Gardner MJ. Statistics with Confidence Second Edition: BMJ Books; 2000."},{"key":"2024112003053912000_2024.11.14.24317340v1.20","unstructured":"Statistics SS. Z Score Calculator for 2 Population Proportions. [cited 11\/28\/2022]; Available from: https:\/\/www.socscistatistics.com\/tests\/ztest\/default2.aspx"},{"issue":"2","key":"2024112003053912000_2024.11.14.24317340v1.21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.10.012","article-title":"Subcutaneous Heparin Therapy for Patients with Cancer-Associated Stroke","volume":"28","year":"2019","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"9","key":"2024112003053912000_2024.11.14.24317340v1.22","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.amjmed.2018.04.037","article-title":"Arterial Ischemic Events Are a Major Complication in Cancer Patients with Venous Thromboembolism","volume":"131","year":"2018","journal-title":"Am J Med"},{"issue":"9","key":"2024112003053912000_2024.11.14.24317340v1.23","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.04.021","article-title":"Antithrombotic Therapy Strategy for Cancer-Associated Ischemic Stroke: A Case Series of 26 Patients","volume":"27","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"12","key":"2024112003053912000_2024.11.14.24317340v1.24","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1016\/j.jstrokecerebrovasdis.2017.07.029","article-title":"Treatment of Cryptogenic Stroke with Active Cancer with a New Oral Anticoagulant","volume":"26","year":"2017","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"5","key":"2024112003053912000_2024.11.14.24317340v1.25","doi-asserted-by":"crossref","first-page":"e743","DOI":"10.1097\/FJC.0000000000001112","article-title":"Nonvitamin K Antagonist Oral Anticoagulant in Patients With Venous Thromboembolism and Polycythemia Vera or Essential Thrombocythemia: A Cohort Study","volume":"78","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"2024112003053912000_2024.11.14.24317340v1.26","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/ene.14172","article-title":"Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial","volume":"27","year":"2020","journal-title":"Eur J Neurol"},{"key":"2024112003053912000_2024.11.14.24317340v1.27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.thromres.2021.08.016","article-title":"Therapeutic efficacy of heparin and direct factor Xa inhibitors in cancer-associated cryptogenic ischemic stroke with venous thromboembolism","volume":"206","year":"2021","journal-title":"Thromb Res"},{"key":"2024112003053912000_2024.11.14.24317340v1.28","doi-asserted-by":"crossref","unstructured":"Zeng S , Zheng Y , Jiang J , Ma J , Zhu W , Cai X . Effectiveness and Safety of DOACs vs. Warfarin in Patients With Atrial Fibrillation and Frailty: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2022;9:907197.","DOI":"10.3389\/fcvm.2022.907197"},{"key":"2024112003053912000_2024.11.14.24317340v1.29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.amjcard.2020.10.064","article-title":"Meta-Analysis of Safety and Efficacy of Direct Oral Anticoagulants Versus Warfarin According to Time in Therapeutic Range in Atrial Fibrillation","volume":"140","year":"2021","journal-title":"Am J Cardiol"},{"issue":"1","key":"2024112003053912000_2024.11.14.24317340v1.30","first-page":"12","article-title":"Atrial fibrillation in cancer patients who develop stroke","volume":"8","year":"2022","journal-title":"Cardiooncology"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.11.14.24317340","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:20:22Z","timestamp":1768508422000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.11.14.24317340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,15]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1101\/2024.11.14.24317340","relation":{},"subject":[],"published":{"date-parts":[[2024,11,15]]},"subtype":"preprint"}}